Azenta (AZTA): Exploring Whether the Recent Share Price Slide Signals a Valuation Opportunity
Azenta (AZTA) has been drifting lately, with the stock down roughly 5% over the month and more than 30% over the past year, even as revenue and net income keep growing.
See our latest analysis for Azenta.
That slide lines up with a 1 year total shareholder return of about negative 34%, even though the 90 day share price return of 5.0% hints that sentiment may be stabilising rather than collapsing further at the current 33.39 dollars level.
If you are weighing where to deploy fresh capital in healthcare tools and services, it might help to compare Azenta with other specialised healthcare stocks that are capturing investor attention.
With shares still well below their highs despite steady revenue and profit growth, and trading at a notable discount to analyst targets, the key question is whether Azenta is now a mispriced opportunity or if markets are already accounting for its future growth.
Most Popular Narrative Narrative: 16.2% Undervalued
With Azenta last closing at 33.39 dollars versus a narrative fair value near 39.83 dollars, the valuation story leans toward upside if its growth path holds.
The analysts have a consensus price target of $33.0 for Azenta based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $30.0.
Curious how modest revenue growth, margin rebuild and a rich future earnings multiple can still justify a premium fair value tag? Want to see the full playbook?
Result: Fair Value of $39.83 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, persistent order delays and ongoing softness in legacy sequencing revenues could undermine revenue growth, margin expansion, and the case for a sustained re rating.
Find out about the key risks to this Azenta narrative.
Build Your Own Azenta Narrative
If you see the numbers differently or want to stress test your own assumptions, spin up a personalised Azenta narrative in under three minutes: Do it your way.
A great starting point for your Azenta research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
Ready for more high conviction ideas?
Before you move on, put Simply Wall St to work and lock in a watchlist of fresh opportunities that match your style, strategy and risk appetite.
- Capture early stage potential by tracking these 3571 penny stocks with strong financials that already show balance sheet strength instead of relying on hype alone.
- Power up your growth watchlist by targeting these 25 AI penny stocks positioned at the intersection of AI innovation and scalable business models.
- Lock onto value opportunities by zeroing in on these 875 undervalued stocks based on cash flows where cash flow strength contrasts sharply with current market pessimism.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com